Floatz logo

ave1625

Dyslipidemia

SanofiPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

21 Active assets in the Dyslipidemia cohort.

Asset / SponsorPhaseRating
Lipitor
Johns Hopkins University
Phase 4A
Rosuvastatin
Korea University Anam Hospital
Phase 4A
Metformin
RenJi Hospital
Phase 4BBB
Ezetimibe
Samsung Medical Center
Phase 4BBB
SIMVASTATIN
Eli Lilly and Company
Phase 4BBB

View all 50 →

Same molecule, other indications

ave1625 is also rated in:

schizophreniaDormant
CCC
Indicative ·
48 / 100
View asset →
obesity disorderDormant
CCC
Indicative ·
48 / 100
View asset →
Alzheimer diseaseDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →